Press release
Investigation announced for Long-Term Investors in shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX)
An investigation on behalf of investors in Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares over potential wrongdoing.
Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Mirati Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. Mirati Therapeutics, Inc. reported that its annual Total Revenue declined from $72.09 million in 2021 to $12.43 million in 2022, and that its Net Loss increased from $581.78 million in 2021 to $740.86 million in 2022.
Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) declined from $101.30 per share on November 28, 2022 delcined to $35.85 per share on April 04, 2023.
Those who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) here
News-ID: 3041915 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Mirati
KRAS Inhibitors Market Set for Dynamic Growth with Key Players Mirati Therapeuti …
Worldwide Market Reports has added a new research study on the Global "KRAS Inhibitors Market" 2025 by Size, Growth, Trends, and Dynamics, Forecast to 2032 which is a result of an extensive examination of the market patterns. This report covers a comprehensive investigation of the information that influences the market regarding fabricates, business providers, market players, and clients. The report provides data about the aspects which drive the expansion of…
Neurofibrosarcoma Market Is Expected to Expand at a Healthy Growth Rate During t …
DelveInsight's "Neurofibrosarcoma Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Neurofibrosarcoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
[https://www.delveinsight.com/report-store/neurofibrosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size…
Colorectal Cancer Pipeline, FDA Approvals, Clinical Trials Development and Compa …
DelveInsight's, "Colorectal Cancer Pipeline Insight" report provides comprehensive insights about 145+ companies and 150+ pipeline drugs in the Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Colorectal…
Histone Deacetylase Inhibitors Market 2023 | Futuristic Trends- Onxeo, Acetylon …
The Histone Deacetylase Inhibitors research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the Histone Deacetylase Inhibitors research report offers information and thoughtful facts like share, revenue, historical data, and global market share. It also highlights vital aspects like opportunities, driving, product scope, market overview, and driving force.
Download FREE Sample Report…
Investigation announced for NASDAQ: MRTX Investors over possible Wrongdoing at M …
Certain directors of Mirati Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.
Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Mirati Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based Mirati…
Investigation announced for Investors in NASDAQ: MRTX shares over possible Viola …
Mirati Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Mirati Therapeutics, Inc. (NASDAQ: MRTX) concerning whether a series of…
